10/08/2025
Geno-Biotic Drug Discovery Info Enterprises (Canada)
Microbial & Human Drug Discovery
Port Coquitlam
Canada
Toll free: +011-2369836419
Phone: +011-236-983-6419
Fax: +011 604-941-9022
E-Mail: [email protected]
Description:
New Discoveries in Biopharma/Orthopharm, Vaccines and Polymeric Like Proteins (PLPs) with Biotech.
By D. A. Flores
As we gather the latest reports for sequencing genomes like the human variety is clocked at 10 mins (e. g. MGI Tech's sequencer model, the DNBSEQ-T7). We assume this hi-throughput is not only true for time but also capacity in samples handling. This will be employed with what is referred to in Bioinformatics New Generation Sequencing (NGS) together with Data Analysis.
These protocols would have the task or capacity to assemble genomes together, identify mutations and including classifying mutant pathogen strains and with high precision. This can lead to further work for vaccine development including tropical countries and can even also be applied for ensuring food safety.
It has been reported that organizations like the Center for Disease Control (CDC) will employ capacity and data analysis collaboration to track and with analysis respond to regulate public health.
At Skye Blue we are still negotiating use of our exclusive and proprietary reagent analyte, a tagged detergent dye chromophoric molecule to separate and quantify/ID the protein analytes like for biopharma and further down the road sequencing with extreme speed, accuracy and capacity, proteins utilizable for drug discovery with biopharmaceutical applications, ortho-chemical drug design or for mRNA-based vaccines and more conventional type vaccines.
There are new protein-like polymers (PLPs), a new drug material polymer which arrived just awhile ago and "SkyeBlue" thinks possibly, if its molecular length/weight is suited, for an electrophorescing separation column for analysis using the same detergent-dye tagged protocol, and further down the road, other types of PLPs of different structures and applications as in biopolymeric molecular assemblies. Take for e. g., based on nutraceuticals, for designing the candidate polymeric drug "designer" biomaterial for a target "receptor" metabolite application, as in health and nutrition.
Warmest regards to colleagues and friends,
Owner and Principal
Skye Blue (SB) Press Corporation
Poco BC Canada V3B 1G3
+1 (236) 983-6419
[email protected]
W. hum-molgen.org (DE)(EU)
W. sbinternet.ca (CA)(US)
(c) 2025-2059. Skye Blue Press Corporation. Port Coquitlam, BC V3B 1G3 Canada.
